Open Heart

JULY 17, 2023

Methods This observational case-control study included consecutive patients whose non-emergency cardiac intervention has been postponed during COVID-19-related lockdown between 19 March and 30 April 2020 (n=193). The planned intervention was deferred by a median of 23 (19–36) days.

COVID-19 52

COVID-19 Outcomes Cardiovascular Interventions Risk Factors 52

DAIC

APRIL 30, 2024

The drug, dapagliflozin, was initially approved for the treatment of Type 2 diabetes, but it since has been shown to reduce the risk of hospitalization for heart failure and death in patients with serious health problems that include heart and chronic kidney disease and heightened cardiovascular risk.

Heart Failure 105

Heart Failure Hospital Research COVID-19 105

DAIC

APRIL 6, 2024

As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease.

Heart attacks 98

Heart attacks Heart Attack Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease.

Heart attacks 81

Heart attacks Heart Attack Heart Failure Outcomes 81